Raymond James analyst Martin Auster reiterated a Strong Buy rating and $46.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Form 10-Q Edgewise Therapeutics, For: Jun 30August 7, 2025 8:06 AM Edgewise Therapeutics, Inc. (EWTX) Tops Q2 EPS by 8cAugust 7, 2025 8:02 AM Form 8-K Edgewise Therapeutics, For: Aug 07August 7, 2025 8:02 AM Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 8:00 AM Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesAugust 6, 2025 4:02 PM